Protagonist Therapeutics, Inc
PTGX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001377121
In the last 90 days, Protagonist Therapeutics, Inc insiders filed 0 open-market purchases and 2 sales; 346 institutions reported holding it in 13F filings for Q2 2026, worth $9.30B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Protagonist Therapeutics, Inc as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 275
- +3 vs. Q2 2025
- Shares held
- 70.7M
- −267.3K (−0.4%) vs. Q2 2025
- Total value
- $4.70B
- +$772.8M (+19.7%) vs. Q2 2025
- New holders
- 42
- 84 more added
- Sold out
- 39
- 109 more reduced
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PTGX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 346 | $9.30B |
| Q1 2026 | 322 | $8.31B |
| Q4 2025 | 319 | $6.18B |
| Q3 2025 | 275 | $4.70B |
| Q2 2025 | 274 | $3.92B |
| Q1 2025 | 275 | $3.15B |
| Q4 2024 | 241 | $2.44B |
| Q3 2024 | 240 | $2.78B |
| Q2 2024 | 188 | $2.05B |
| Q1 2024 | 185 | $1.73B |
| Q4 2023 | 157 | $1.32B |
| Q3 2023 | 144 | $945.9M |
| Q2 2023 | 167 | $1.57B |
| Q1 2023 | 138 | $1.22B |
| Q4 2022 | 137 | $533.3M |
| Q3 2022 | 133 | $398.9M |
| Q2 2022 | 131 | $422.1M |
| Q1 2022 | 140 | $1.19B |
| Q4 2021 | 149 | $1.68B |
| Q3 2021 | 132 | $820.8M |
| Q2 2021 | 139 | $2.16B |
| Q1 2021 | 127 | $1.15B |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Protagonist Therapeutics, Inc; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Net Worth Advisory Group | 0 | $0 | 0.00% | −5,822−100.0% | Sold out |
| Graham Capital Management, L.P. | 0 | $0 | 0.00% | −4,979−100.0% | Sold out |
| Bridgefront Capital, LLC | 0 | $0 | 0.00% | −4,545−100.0% | Sold out |
| HSBC Holdings PLC | 0 | $0 | 0.00% | −4,340−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −3,985−100.0% | Sold out |
| FNY Investment Advisers, LLC | 0 | $0 | 0.00% | −500−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −487−100.0% | Sold out |
| Twin Peaks Wealth Advisors, LLC | 0 | $0 | 0.00% | −171−100.0% | Sold out |
| Riggs Asset Managment Co. Inc. | 0 | $0 | 0.00% | −71−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | 0 | Sold out |
| Kestra Investment Management, LLC | 0 | $0 | 0.00% | −54−100.0% | Sold out |
| Geneos Wealth Management Inc. | 0 | $0 | 0.00% | −47−100.0% | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −41−100.0% | Sold out |
| Whipplewood Advisors, LLC | 0 | $0 | 0.00% | −22−100.0% | Sold out |
| E Fund Management Co., Ltd. | – | – | – | – | Not filed |
| CIBC World Markets Corp | – | – | – | – | Not filed |